Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit

Drug makers’ settlements of accounts for FY2014, the first full-year settlements since sodium glucose co-transporter-2 (SGLT-2) inhibitors were launched, reveal that sales of these products have remained virtually unchanged since their launch. The fact that manufacturers have refrained from marketing...read more